Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024, JPMorgan ...

In the latest trading session, Amgen (AMGN) closed at $317.17, marking a +1.1% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.64%. Meanwhile, the Dow experienced a ...

Amgen (NASDAQ:AMGN) shares continued gains for seven straight sessions, as the stock closed nearly 1% higher at $327.36 on Monday. The biotechnology company gained over 5% in the preceding six ...

Amgen AMGN reported fourth-quarter 2024 adjusted ... However, weakness in some key brands like Otezla is a headwind. Also, sales of Amgen’s best-selling drugs, Prolia and Xgeva, are expected ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other undervalued stocks. On March 5th, BBC reported that the US stock market had fallen after the ...

Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year Amgen's Uplizna met key endpoints in a Phase 3 gMG trial, showing sustained efficacy and improvement ...

Key Drugs Driving AMGN’s Top Line Amgen is seeing declining ... pressure are hurting sales of many products. Sales of some key brands, like Otezla and Lumakras, have been lukewarm.

In the latest trading session, Amgen (AMGN) closed at $317.17, marking a +1.1% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.64%. Meanwhile, the Dow experienced a rise ...